Tweet This post was created by Dr Tim Jamieson, a Health Economist at the Wolfson Institute of Population Health, Queen Mary University of London about his recent publication in the European Journal of Health Economics. The Health Economic and Policy Research Unit at QMUL has just published a piece of work in conjunction with Dr…
Month: December 2025
Chronic inflammation signals brain atrophy in children with MS: Study
Children with multiple sclerosis (MS) who have more paramagnetic rim lesions (PRLs) — areas of chronic active inflammation seen on MRI scans — tend to lose more brain volume over time, a new study found. These lesions were common in pediatric MS, a rare form of the disease that develops during childhood or adolescence, appearing…
The Reality of Living with SPMS
Hello all, and long time, no speak! I feel rubbish that I haven’t blogged in months but, at the same … The post The Reality of Living with SPMS appeared first on . SPMS and My Body Image Living with a Progressive Chronic illness…. New Meds, New House, New Feelings about My MS… Source: trippingthroughtreacle.com
Why I’m researching clinical trials as I prepare to switch my DMT
I wrote in the summer about changing the disease-modifying therapy (DMT) for my multiple sclerosis (MS). I’ve familiarized myself with the available DMTs, and I plan to ask my neurologist for her recommendation next week and then make a decision. As I’ve researched my options, I’ve become interested in participating in clinical trials. The database…
Holiday Rice Krispie Treats
This easy and festive recipe for classic Holiday Rice Krispie Treats is a crowd pleaser. You can add fun toppings such as red and green M&Ms and holiday sprinkles or any additional toppings you might like. Ingredients Instructions Wishing you all … Continue reading → Source: blog.mymsaa.org
Natalizumab response and genetics
Tweet Fc is the effector end of antibodies the Fab binds to the target. Antibodies kill their targets by cells or other molecules pulling holes in the target via the Fc receptor. Natalizumab works by the front end blocking the target for natalizumab. In terms of killing targets by cells there are genetic variants of…
Risk of Infection from Anti-CD20
Tweet I was at a meeting recently and the manufacturer of a CD20-depleting antibodies had created slides for the speaker that implied that there was no important serious infection risk with their product and I thought this doesn’t really reflect that reported by academics using rituximab. A risk factor is loss of B cells and…
The Blood and Lymph Glands are different
Tweet This study uses a new technique to tell us that the cells in the blood are different to those in the immune organs…it is a bit of a NSS moment for me as we have known this for decades. Cells such as T cells are formed in the bone marrow and then educated in…
How hand weakness led me to a meaningful career in medicine
To call my medical career a series of random pivots is an understatement. I have multiple sclerosis (MS) to thank for this wandering journey, one with an uncertain destination, but a surprisingly meaningful landing place. Anesthesiology was my first love. I adored tinkering with the anesthesia machine, working with powerful anesthetics, and being the quiet…
DMTs that protect brain volume may also slow disability progression
Specific disease-modifying therapies (DMTs) significantly slow the rate of brain volume loss in adults with multiple sclerosis (MS), a benefit that is directly linked to reduced long-term disability, according to a new review. A network meta-analysis of more than 26,000 patients confirms that therapies most effective at preserving brain tissue are also those that can…